No statistical differences in ARHGAP21 expression were observed between the two groups of MDS patients classified according to the WHO-2016 [RS-SLD/RS-MLD/del(5q)/SLD/MLD versus EB-1/EB-2] (Supplementary Figure 2A). This evidence concerns the gene ARHGAP21 and myelodysplastic syndrome.